Monday , December 11 2017
Home / KEEP BUT DO NOT DISPLAY / Did You Know / Inhaled Insulin Therapy Drug Resubmitted for FDA Approval

Inhaled Insulin Therapy Drug Resubmitted for FDA Approval

MannKind again filed an application with the FDA for approval to market its Afrezza inhalation powder, a fast mealtime insulin treatment intended to improve glycemic control for diabetes patients. The application was based on data from two late-stage trials. Mannkind Press Release Oct 2013